公开(公告)号：US20240352021A1

公开(公告)日：2024-10-24

申请号：US18701077

申请日：2022-10-18

Applicant: DANA-FARBER CANCER INSTITUTE, INC. ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  SPRINGWORKS THERAPEUTICS INC

Inventor： JIANWEI CHE ,  ZHENGNIAN LI ,  NATHANAEL S. GRAY ,  TINGHU ZHANG ,  STEPHEN LEYCESTER GWALTNEY, II ,  TYLER BEYETT

IPC: C07D487/04 ,  A61K31/519 ,  A61K31/529 ,  A61K31/549 ,  A61K31/551 ,  A61P35/00 ,  C07D471/04 ,  C07D487/18 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/529 ,  A61K31/549 ,  A61K31/551 ,  A61P35/00 ,  C07D471/04 ,  C07D487/18 ,  C07D519/00

Abstract: The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

公开(公告)号：US12110277B2

公开(公告)日：2024-10-08

申请号：US17929153

申请日：2022-09-01

Applicant: SPRINGWORKS THERAPEUTICS, INC.

Inventor： Kristin Patterson ,  Mark Hatcher

IPC: C07D233/88 ,  C07C227/26 ,  C07D263/44

CPC classification number: C07D233/88 ,  C07C227/26 ,  C07D263/44

Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).

公开(公告)号：US20240307328A1

公开(公告)日：2024-09-19

申请号：US18674104

申请日：2024-05-24

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Uchenna H. ILOEJE ,  Abraham J. LANGSETH ,  Todd Webster SHEARER

IPC: A61K31/166 ,  A61K9/00 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

CPC classification number: A61K31/166 ,  A61K9/0053 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUCO-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.

公开(公告)号：US20240245648A1

公开(公告)日：2024-07-25

申请号：US18624670

申请日：2024-04-02

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Allison Lim ,  Shinta Cheng ,  Todd Webster Shearer ,  Rex Williams ,  Kristin Patterson

IPC: A61K31/417 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/417 ,  A61K9/0053 ,  A61P35/00

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

公开(公告)号：US12029711B1

公开(公告)日：2024-07-09

申请号：US18608735

申请日：2024-03-18

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Piero L. Ruggiero ,  Kristin Patterson ,  Mark Hatcher ,  Jiping Liu ,  Uchenna H. Iloeje ,  Abraham J. Langseth

IPC: A61K31/166 ,  A61K9/00 ,  A61K9/48

CPC classification number: A61K31/166 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

公开(公告)号：US20240216305A1

公开(公告)日：2024-07-04

申请号：US18609687

申请日：2024-03-19

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Uchenna H. ILOEJE ,  Abraham J. LANGSETH ,  Todd Webster SHEARER

IPC: A61K31/166 ,  A61K9/00 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

CPC classification number: A61K31/166 ,  A61K9/0053 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.

公开(公告)号：US20240122881A1

公开(公告)日：2024-04-18

申请号：US18487237

申请日：2023-10-16

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Todd SHEARER

IPC: A61K31/165 ,  A61K31/4375

CPC classification number: A61K31/165 ,  A61K31/4375

Abstract: The present disclosure relates to methods of treating cancers comprising co-administration of mirdametinib (Compound A) or a pharmaceutically acceptable salt thereof, and 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(2,4,5-trifluorophenyl) urea (Compound B) or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

公开(公告)号：US11938116B2

公开(公告)日：2024-03-26

申请号：US18491283

申请日：2023-10-20

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Allison Lim ,  Shinta Cheng ,  Todd Webster Shearer ,  Rex Williams ,  Kristin Patterson

IPC: A61K31/4164 ,  A61P35/00

CPC classification number: A61K31/4164 ,  A61P35/00

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

公开(公告)号：US20240091197A1

公开(公告)日：2024-03-21

申请号：US18491323

申请日：2023-10-20

Applicant: SpringWorks Therapeutics, Inc.

Inventor： Allison Lim ,  Shinta Cheng ,  Todd Webster Shearer ,  Rex Williams ,  Kristin Patterson

IPC: A61K31/4164 ,  A61P35/00

CPC classification number: A61K31/4164 ,  A61P35/00

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

公开(公告)号：US11806321B2

公开(公告)日：2023-11-07

申请号：US18185045

申请日：2023-03-16

Applicant: SpringWorks Therapeutics Inc.

Inventor： Uchenna H Iloeje ,  Abraham J Langseth ,  Todd Shearer

IPC: A61K31/166 ,  A61P25/00 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/166 ,  A61K9/0053 ,  A61P25/00 ,  A61P35/00

Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.